​

Aerovate Therapeutics Stock (NASDAQ:AVTE)

ForecastOwnershipFinancialsChart
Aerovate Therapeutics by TradingView

Previous Close

$2.66

52W Range

$1.25 - $25.58

50D Avg

$2.49

200D Avg

$2.27

Market Cap

$78.25M

Avg Vol (3M)

$139.26K

Beta

0.95

Div Yield

-

AVTE Company Profile

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

30

IPO Date

Jun 30, 2021

Website

AVTE Performance

AVTE Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-74.60M$-81.41M$-53.24M
Net Income$-69.63M$-75.52M$-51.51M
EBITDA$-74.31M$-81.31M$-53.17M
Basic EPS$-2.44$-2.87$-2.10
Diluted EPS$-2.44$-2.87$-2.10

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
MLYSMineralys Therapeutics, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
ADAGAdagene Inc.
OPTOpthea Limited
RZLTRezolute, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
ANTXAN2 Therapeutics, Inc.